IVIM Health tirzepatide: November 2026 price and position
As of November 20, 2026, IVIM Health charges $192 a month for compounded tirzepatide month to month, all-in, according to its own page. That is a starting-dose figure; the price rises with the dose, so ask for the maintenance-dose price in writing.
Released · Last reviewed · how we verify
IVIM Health tirzepatide prices, read November 20, 2026
| Measure | Amount | Basis |
|---|---|---|
| Month to month, all-in | from $192 | per month, starting-dose price |
| Lowest printed rate | $192 | $117 + $75 program fee |
FDA warning letters
FDA’s warning-letter index lists warning letter 721816 (dated February 20, 2026, subject “False & Misleading Claims/Misbranded (Telehealth)”) to IVIM Health; no close-out letter is listed. A warning letter is FDA’s formal notice of alleged violations, not a recall, ban or court finding.
Limitations and what to check before you enroll
Compounded tirzepatide is not FDA-approved and is not the same product as Zepbound; it is made for an individual patient by a state-licensed pharmacy. Ask IVIM Health for the all-in price at the maintenance dose, what is charged today and how often, and which pharmacy fills the prescription. A clinician decides whether any GLP-1 is right for you.
Frequently asked
How much does IVIM Health charge for tirzepatide?
As of November 20, 2026, IVIM Health charges $192 a month for compounded tirzepatide month to month, all-in, according to its own page. That is a starting-dose figure; the price rises with the dose, so ask for the maintenance-dose price in writing.
Is IVIM Health’s tirzepatide FDA-approved?
No. Compounded tirzepatide from any telehealth program, IVIM Health included, is not FDA-approved and is not the same product as Zepbound or Mounjaro. It is made for an individual patient by a state-licensed compounding pharmacy. Brand Zepbound is the FDA-approved version.
Where do these IVIM Health figures come from?
From IVIM Health’s own page (first-party read, November 20, 2026), converted to an all-in month-to-month figure (medication plus any required recurring fee, before tax). The source link and read date are listed below, and the same figures are in the open dataset.
Sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026; read November 20, 2026)
- Federal Register 91 FR 23431: proposed 503B bulks-list decision for semaglutide, tirzepatide and liraglutide (May 1, 2026; no final notice found as of November 20, 2026)
- Zepbound (tirzepatide) prescribing information on DailyMed (read November 20, 2026)
- Wegovy (semaglutide) prescribing information on DailyMed (read November 20, 2026)
- IVIM Health pricing page (read November 20, 2026)
- FDA warning letter 721816 to IVIM Health (dated 2026-02-20, posted 2026-03-03; read November 20, 2026)